Advertisement

Der Onkologe

pp 1–16 | Cite as

Konjunktivale Malignome

  • Claudia Auw-HädrichEmail author
  • Thomas Reinhard
CME
  • 7 Downloads

Zusammenfassung

Malignome der Bindehaut sind selten. Dennoch gehören einige dieser Tumoren zu den bösartigsten in der Ophthalmologie, und sie erfordern radikale Therapien, die ggf. zu Erblindung bzw. Verlust des ipsilateralen Auges und tumorassoziiertem Tod führen. Die für den Onkologen relevantesten primären Malignome der Bindehaut sind das Plattenepithelkarzinom, das maligne Melanom und das maligne Lymphom. Die chirurgische Therapie steht beim Plattenepithelkarzinom und malignen Melanom im Vordergrund. Eine adjuvante Therapie in Form von topischer Chemotherapie bzw. Bestrahlung ist meist erforderlich. Das isolierte maligne Lymphom der Bindehaut wird möglichst exzisional biopsiert. War eine inzisionale Biopsie unumgänglich, sollte zusätzlich bestrahlt werden; in der Regel spricht das maligne Lymphom bereits auf relativ niedrige Bestrahlungsdosen sehr gut an, mit guter Prognose quoad vitam. Auch aggressivere Formen, wie das diffus großzellige B‑Zell-Lymphom oder das Mantelzelllymphom, müssen ebenfalls schon in frühen Stadien systemisch behandelt werden.

Schlüsselwörter

Bindehauttumoren Plattenepithelkarzinom Melanom Malignes Lymphom Metastasen 

Conjunctival malignancies

Abstract

Conjunctival malignancies are rare. However, some of these tumors are among the most aggressive malignancies in ophthalmology and require radical forms of therapy that may lead to blindness or loss of the ipsilateral eye and tumor-associated death. The most relevant primary conjunctival malignancies for oncologists are squamous cell carcinoma, malignant melanoma and malignant lymphoma. Surgical therapy is the primary treatment for squamous cell carcinoma and malignant melanoma. An adjuvant therapy in the form of topical chemotherapy or radiation is necessary in most cases. The isolated malignant lymphoma of the conjunctiva is biopsied excisionally if possible. However, if an incisional biopsy was unavoidable, additional irradiation should be performed; malignant lymphoma generally responds very well to relatively low irradiation doses with a good prognosis quad vitam. More aggressive forms, such as diffuse large cell B‑cell lymphoma or mantle cell lymphoma, must also be treated systemically at an early stage.

Keywords

Conjunctival neoplasms Carcinoma, squamous cell Melanoma Lymphoma Neoplasm metastasis 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

Gemäß den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollständige Erklärung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.

Autoren

C. Auw-Hädrich gibt an, dass kein finanzieller Interessenkonflikt besteht. Nichtfinanzielle Interessen: Angestellte Ophthalmologin, Oberärztin, Klinik für Augenheilkunde, Universität Freiburg. T. Reinhard gibt an, dass kein Interessenkonflikt besteht.

Der Verlag

erklärt, dass für die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag fließen.

Wissenschaftliche Leitung

Die vollständige Erklärung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf www.springermedizin.de/cme.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Emmanuel B, Ruder E, Lin S‑W et al (2012) Incidence of squamous-cell carcinoma of the conjunctiva and other eye cancers in the NIH-AARP Diet and Health Study. Ecancermedicalscience 6:254.  https://doi.org/10.3332/ecancer.2012.254 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Sun EC, Fears TR, Goedert JJ (1997) Epidemiology of squamous cell conjunctival cancer. Cancer Epidemiol Biomarkers Prev 6:73–77PubMedGoogle Scholar
  3. 3.
    Lee GA, Hirst LW (1992) Incidence of ocular surface epithelial dysplasia in metropolitan Brisbane. A 10-year survey. Arch Ophthalmol 110(1960):525–527CrossRefGoogle Scholar
  4. 4.
    Gichuhi S, Sagoo MS, Weiss HA, Burton MJ (2013) Epidemiology of ocular surface squamous neoplasia in Africa. Trop Med Int Health 18:1424–1443.  https://doi.org/10.1111/tmi.12203 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Sjö LD, Ralfkiaer E, Prause JU et al (2008) Increasing incidence of ophthalmic lymphoma in Denmark from 1980 to 2005. Invest Ophthalmol Vis Sci 49:3283–3288.  https://doi.org/10.1167/iovs.08-1768 CrossRefPubMedGoogle Scholar
  6. 6.
    Yu G‑P, Hu D‑N, McCormick S, Finger PT (2003) Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol 135:800–806CrossRefGoogle Scholar
  7. 7.
    Tuomaala S, Kivelä T (2003) Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol 136:1189–1190 (author reply 1190)CrossRefGoogle Scholar
  8. 8.
    Grossniklaus HE, Eberhart CG, Kivelä TT (2018) WHO classification of tumours of the eye, 4. Aufl. IARC (International Agency for the Research on Cancer) Publications, LyonGoogle Scholar
  9. 9.
    Parrozzani R, Frizziero L, Trainiti S et al (2017) Topical 1 % 5‑fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study. Br J Ophthalmol 101:1094–1099.  https://doi.org/10.1136/bjophthalmol-2016-309219 CrossRefPubMedGoogle Scholar
  10. 10.
    Gates AE, Kaplan LD (2002) AIDS malignancies in the era of highly active antiretroviral therapy. Oncology 16:441–451, 456, 459PubMedGoogle Scholar
  11. 11.
    Bredow L, Martin G, Reinhard T et al (2009) Recurrent conjunctival papilloma progressing into squamous cell carcinoma with change of HPV-finding during the course. Br J Ophthalmol 93:1437, 1451.  https://doi.org/10.1136/bjo.2007.132852 CrossRefPubMedGoogle Scholar
  12. 12.
    Auw-Haedrich C, Martin G, Spelsberg H et al (2008) Expression of p16 in conjunctival intraepithelial neoplasia does not correlate with HPV-infection. Open Ophthalmol J 2:48–56.  https://doi.org/10.2174/1874364100802010048 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Eng H‑L, Lin T‑M, Chen S‑Y et al (2002) Failure to detect human papillomavirus DNA in malignant epithelial neoplasms of conjunctiva by polymerase chain reaction. Am J Clin Pathol 117:429–436.  https://doi.org/10.1309/RVUP-QMU3-5X6W-3CQ1 CrossRefPubMedGoogle Scholar
  14. 14.
    Kallen C, Reinhard T, Schilgen G et al (2003) Atopic keratoconjunctivitis: probably a risk factor for the development of conjuntival carcinoma. Ophthalmologe 100:808–814.  https://doi.org/10.1007/s00347-003-0809-z CrossRefPubMedGoogle Scholar
  15. 15.
    McKelvie PA, Daniell M, McNab A et al (2002) Squamous cell carcinoma of the conjunctiva: a series of 26 cases. Br J Ophthalmol 86:168–173CrossRefGoogle Scholar
  16. 16.
    Wittekind C (2017) TNM: Klassifikation maligner Tumoren, 8. Aufl. Wiley, WeinheimGoogle Scholar
  17. 17.
    Siedlecki AN, Tapp S, Tosteson ANA et al (2016) Surgery versus interferon Alpha-2b treatment strategies for ocular surface squamous neoplasia: a literature-based decision analysis. Cornea 35:613–618.  https://doi.org/10.1097/ICO.0000000000000766 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    El-Sawy T, Sabichi AL, Myers JN et al (2012) Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol 130:1608–1611.  https://doi.org/10.1001/archophthalmol.2012.2515 CrossRefPubMedGoogle Scholar
  19. 19.
    Galor A, Karp CL, Oellers P et al (2012) Predictors of ocular surface squamous neoplasia recurrence after excisional surgery. Ophthalmology 119:1974–1981.  https://doi.org/10.1016/j.ophtha.2012.04.022 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ramberg I, Heegaard S, Prause JU et al (2015) Squamous cell dysplasia and carcinoma of the conjunctiva. A nationwide, retrospective, epidemiological study of Danish patients. Acta Ophthalmol (Copenh) 93:663–666.  https://doi.org/10.1111/aos.12743 CrossRefGoogle Scholar
  21. 21.
    Tabbara KF, Kersten R, Daouk N, Blodi FC (1988) Metastatic squamous cell carcinoma of the conjunctiva. Ophthalmology 95:318–321CrossRefGoogle Scholar
  22. 22.
    Westekemper H, Schallenberg M, Tomaszewski A et al (2011) Malignant epibulbar tumours: new strategies in diagnostics and therapy. Klin Monatsbl Augenheilkd 228:780–792.  https://doi.org/10.1055/s-0029-1246068 CrossRefPubMedGoogle Scholar
  23. 23.
    Jakobiec FA, Folberg R, Iwamoto T (1989) Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva. Ophthalmology 96:147–166CrossRefGoogle Scholar
  24. 24.
    Shields CL, Chien JL, Surakiatchanukul T et al (2017) Conjunctival tumors: review of clinical features, risks, biomarkers, and outcomes--the 2017 J. Donald M. Gass lecture. Asia Pac J Ophthalmol 6:109–120.  https://doi.org/10.22608/APO.201710 CrossRefGoogle Scholar
  25. 25.
    Damato B, Coupland SE (2008) Conjunctival melanoma and melanosis: a reappraisal of terminology, classification and staging. Clin Exp Ophthalmol 36:786–795.  https://doi.org/10.1111/j.1442-9071.2008.01888.x CrossRefPubMedGoogle Scholar
  26. 26.
    Koopmans AE, Ober K, Dubbink HJ et al (2014) Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions. Invest Ophthalmol Vis Sci 55:6024–6030.  https://doi.org/10.1167/iovs.14-14901 CrossRefPubMedGoogle Scholar
  27. 27.
    Griewank KG, Westekemper H, Murali R et al (2013) Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res 19:3143–3152.  https://doi.org/10.1158/1078-0432.CCR-13-0163 CrossRefPubMedGoogle Scholar
  28. 28.
    Pache M, Glatz-Krieger K, Sauter G, Meyer P (2006) Expression of sex hormone receptors and cell cycle proteins in melanocytic lesions of the ocular conjunctiva. Graefes Arch Clin Exp Ophthalmol 244:113–117.  https://doi.org/10.1007/s00417-005-0035-2 CrossRefPubMedGoogle Scholar
  29. 29.
    Auw-Hädrich C, Reinhard T (2006) Bindehautmelanom. Z Prakt Augenheilkd 27:244–250Google Scholar
  30. 30.
    Vora GK, Demirci H, Marr B, Mruthyunjaya P (2017) Advances in the management of conjunctival melanoma. Surv Ophthalmol 62:26–42.  https://doi.org/10.1016/j.survophthal.2016.06.001 CrossRefPubMedGoogle Scholar
  31. 31.
    Kikuchi I, Kase S, Ishijima K, Ishida S (2017) Long-term follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resection. Graefes Arch Clin Exp Ophthalmol 255:2271–2276.  https://doi.org/10.1007/s00417-017-3754-2 CrossRefPubMedGoogle Scholar
  32. 32.
    Damato B, Coupland SE (2009) An audit of conjunctival melanoma treatment in Liverpool. Eye 23:801–809.  https://doi.org/10.1038/eye.2008.154 CrossRefPubMedGoogle Scholar
  33. 33.
    Wuestemeyer H, Sauerwein W, Meller D et al (2006) Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma. Graefes Arch Clin Exp Ophthalmol 244:438–446.  https://doi.org/10.1007/s00417-005-0093-5 CrossRefPubMedGoogle Scholar
  34. 34.
    Pahlitzsch M, Bertelmann E, Mai C (2014) Conjunctival melanoma and BRAF inhibitor therapy. J Clin Exp Ophthalmol 5:322CrossRefGoogle Scholar
  35. 35.
    Shields CL, Kaliki S, Al-Dahmash SA et al (2012) American Joint Committee on Cancer (AJCC) clinical classification predicts conjunctival melanoma outcomes. Ophthal Plast Reconstr Surg 28:313–323.  https://doi.org/10.1097/IOP.0b013e3182611670 CrossRefPubMedGoogle Scholar
  36. 36.
    Larsen A‑C, Dahl C, Dahmcke CM et al (2016) BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions. Acta Ophthalmol 94:463–470.  https://doi.org/10.1111/aos.13007 CrossRefPubMedGoogle Scholar
  37. 37.
    Glossmann J‑P, Skoetz N, Starbatty B et al (2018) Conjunctival melanoma : Standard operating procedures in diagnosis, treatment and follow-up care. Ophthalmologe 115:489–498.  https://doi.org/10.1007/s00347-018-0664-6 CrossRefPubMedGoogle Scholar
  38. 38.
    Coupland SE, Krause L, Delecluse HJ et al (1998) Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases. Ophthalmology 105:1430–1441.  https://doi.org/10.1016/S0161-6420(98)98024-1 CrossRefPubMedGoogle Scholar
  39. 39.
    Kirkegaard MM, Coupland SE, Prause JU, Heegaard S (2015) Malignant lymphoma of the conjunctiva. Surv Ophthalmol 60:444–458.  https://doi.org/10.1016/j.survophthal.2015.05.001 CrossRefPubMedGoogle Scholar
  40. 40.
    Rasmussen PK (2013) Diffuse large B‑cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features. Acta Ophthalmol 5:1–27.  https://doi.org/10.1111/aos.12189 (91 Thesis)CrossRefGoogle Scholar
  41. 41.
    Kirkegaard MM, Rasmussen PK, Coupland SE et al (2016) Conjunctival lymphoma—an international multicenter retrospective study. Jama Ophthalmol 134:406–414.  https://doi.org/10.1001/jamaophthalmol.2015.6122 CrossRefPubMedGoogle Scholar
  42. 42.
    Sniegowski MC, Roberts D, Bakhoum M et al (2014) Ocular adnexal lymphoma: validation of American Joint Committee on Cancer seventh edition staging guidelines. Br J Ophthalmol 98:1255–1260.  https://doi.org/10.1136/bjophthalmol-2013-304847 CrossRefPubMedGoogle Scholar
  43. 43.
    Rath S, Connors JM, Dolman PJ et al (2014) Comparison of American Joint Committee on Cancer TNM-based staging system (7th edition) and Ann Arbor classification for predicting outcome in ocular adnexal lymphoma. Orbit 33:23–28.  https://doi.org/10.3109/01676830.2013.842257 CrossRefPubMedGoogle Scholar
  44. 44.
    Suesskind D, Ziemssen F, Rohrbach JM (2015) Conjunctival amyloidosis—clinical and histopathologic features. Graefes Arch Clin Exp Ophthalmol 253:1377–1383.  https://doi.org/10.1007/s00417-015-2932-3 CrossRefPubMedGoogle Scholar
  45. 45.
    Yen MT, Bilyk JR, Wladis EJ et al (2018) Treatments for ocular adnexal lymphoma: a report by the American Academy of Ophthalmology. Ophthalmology 125:127–136.  https://doi.org/10.1016/j.ophtha.2017.05.037 CrossRefPubMedGoogle Scholar
  46. 46.
    Pinnix CC, Dabaja BS, Milgrom SA et al (2017) Ultra-low-dose radiotherapy for definitive management of ocular adnexal B‑cell lymphoma. Head Neck 39:1095–1100.  https://doi.org/10.1002/hed.24717 CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Schmitz N, Nickelsen M, Ziepert M et al (2012) Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B‑cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 13:1250–1259.  https://doi.org/10.1016/S1470-2045(12)70481-3 CrossRefPubMedGoogle Scholar
  48. 48.
    Geisler CH, Kolstad A, Laurell A et al (2012) Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 158:355–362.  https://doi.org/10.1111/j.1365-2141.2012.09174.x CrossRefPubMedGoogle Scholar
  49. 49.
    Coupland SE, Heegaard S, Loeffler KU et al (2018) Haematolymphoid tumours of the conjunctiva and caruncle. In: Grossniklaus HE, Eberhart CG, Kivelä TT (Hrsg) WHO classification of tumours of the eye, 4. Aufl. International Agency for Research on Cancer, Lyon, S 40–41Google Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Augenheilkunde FreiburgFreiburgDeutschland

Personalised recommendations